Initial therapy with protease inhibitor-sparing regimens: evaluation of nevirapine and delavirdine

Area of Science:

• Infectious Diseases
• Virology
• Immunology

Background:

• Antiretroviral therapy is crucial for managing HIV infection.
• Protease inhibitors (PIs) are a cornerstone of HIV treatment.
• Drug-naive patients require effective initial antiretroviral regimens.

Purpose of the Study:

• To compare the efficacy of two protease inhibitor-sparing regimens in drug-naive HIV patients.
• To evaluate viral load reduction and CD4 T cell count increases.
• To assess the potential of nonnucleoside reverse transcriptase inhibitors (NNRTIs) as an alternative to PIs.

Main Methods:

• On-treatment analysis of two randomized clinical trials (INCAS and protocol 0021 Part II).
• Comparison of regimens: zidovudine/didanosine/nevirapine vs. zidovudine/lamivudine/delavirdine.
• Assessment of plasma viral load and CD4 T cell counts over 52 weeks.

Main Results:

• Both regimens achieved similar mean viral load decreases (2.2 and 2.1 log(10) copies/mL).
• Maximal viral suppression rates were comparable (45% and 59%).
• Mean CD4 T cell count increases were observed (139 and 88 cells/microL).

Conclusions:

• The two triple-drug regimens demonstrated similar virologic and immunologic efficacy.
• NNRTIs may serve as a valuable alternative to PIs in initial HIV therapy for certain patients.
• Long-term study results are needed to determine the preferred initial treatment approach.